Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease

(2018) Geert D’Haens et al.   GASTROENTEROLOGY

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

(2017) Kristin K Jørgensen et al.   LANCET

Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis

(2016) Konstantinos Papamichael et al.   Clinical Gastroenterology and Hepatology

Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease

(2016) Lieven Pouillon et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies

(2016) Casper Steenholdt et al.   INFLAMMATORY BOWEL DISEASES

Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis

(2016) M. Anthony Sofia et al.   Therapeutic Advances in Gastroenterology

Serum Infliximab Concentrations in Psoriatic Patients Treated with Infliximab: A Systematic Review

(2015) C Dannepond et al.   ACTA DERMATO-VENEREOLOGICA

Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting

(2015) Andrea Warman et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima

(2015) Shomron Ben-Horin et al.   GUT

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis

(2015) Taku Kobayashi et al.   JOURNAL OF GASTROENTEROLOGY

Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis

(2014) Omoniyi J. Adedokun et al.   GASTROENTEROLOGY

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease

(2014) Niels Vande Casteele et al.   GUT

Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study

(2014) Tsutomu Takeuchi et al.   Modern Rheumatology

A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies

(2013) Sandra Garcês et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

(2013) Dae Hyun Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

(2013) Won Park et al.   ANNALS OF THE RHEUMATIC DISEASES

Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population

(2013) Maxine D. Fisher et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: A systematic review of cohort studies with focus on dose

(2013) Grith Eng et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Immunogenicity of Monoclonal Antibodies Against Tumor Necrosis Factor Used in Chronic Immune-Mediated Inflammatory Conditions

(2013) Jose Ramon Maneiro et al.   JAMA Internal Medicine

Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis

(2012) Kavinderjit S Nanda et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis

(2012) Sandra Garcês et al.   ANNALS OF THE RHEUMATIC DISEASES

Doubling the infliximab dose versus halving the infusion intervals in Crohnʼs disease patients with loss of response

(2012) Lior Katz et al.   INFLAMMATORY BOWEL DISEASES

Assessing Response and Loss of Response to Biological Therapies in IBD

(2011) Henit Yanai et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab

(2010) U. Kopylov et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice

(2010) M. Blom et al.   ARTHRITIS CARE & RESEARCH